



## A message from Magnus

Dear friends,

In line with AstraZeneca’s **Growth Through Innovation** strategy, the BioVentureHub has now orchestrated the inclusion of 41 external companies (incl. 10 alumni companies) and research groups to co-locate with us at the AstraZeneca Gothenburg site.

We’re proud to help foster an **open, inclusive and diverse culture** that facilitates collaboration, drives innovation and exposes AstraZeneca to a wider diversity of science and ways of working.


In the midst of the Corona pandemic, we continue to develop our operations and our offering. During Q3, we doubled-down on our ambition to harness the power of **digital health** and to catalyse collaboration and connections between the digital health community and AstraZeneca.

### Welcome Anders Persson!

In September, we announced that Anders Persson, currently Digital Transformation Lead in AstraZeneca’s Digital Health R&D team, would be joining the BioVentureHub in Gothenburg on a 50% secondment as of October 1.

Collaborating closely with AstraZeneca functions, Anders is now developing and driving the strategy to maximise the potential of the BioVentureHub to attract relevant digital health companies to collaborate more closely with AstraZeneca.

### BioVentureHub and IBM Accelerator program



How does IBM engage?	What are the benefits?	Contact
<p><b>Provide expert advice</b></p> <ul style="list-style-type: none"> <li>Identify &amp; target key players</li> <li>Develop &amp; launch key initiatives</li> <li>Monitor &amp; evaluate progress</li> </ul> <p><b>How can we benefit?</b></p> <ul style="list-style-type: none"> <li>IBM can help you:</li> <li>Identify &amp; target key players</li> <li>Develop &amp; launch key initiatives</li> <li>Monitor &amp; evaluate progress</li> </ul>	<p><b>Gain insights into the market</b></p> <ul style="list-style-type: none"> <li>Market insights</li> <li>Competitive analysis</li> <li>Customer insights</li> <li>Operational insights</li> </ul> <p><b>How can we benefit?</b></p> <ul style="list-style-type: none"> <li>Gain insights into the market</li> <li>Competitive analysis</li> <li>Customer insights</li> <li>Operational insights</li> </ul>	<p><b>How to contact</b></p> <ul style="list-style-type: none"> <li>IBM Business Partner</li> <li>IBM Accelerator</li> <li>IBM Business Partner</li> </ul>

We continue to develop [our collaboration with IBM Sweden](#) to support knowledge exchange between the life science and digital technology industries, and strengthen digital health expertise.

We have published [a one-pager document](#) summarizing the support and benefits that SMEs can gain by accessing the program.

### **MDR webinar**

Collaborating with Mölnlycke, AstraZeneca and Devicia, we hosted an open webinar “Successfully navigating MDR transition” which aimed to inspire Sweden-based, small & medium sized companies (SMEs) how to navigate the transition towards alignment with the new EU Medical Device Regulation (MDR).

If you are a SME and would like to receive the presentation, contact [Amanda.Lantz@devicia.com](mailto:Amanda.Lantz@devicia.com)

Collaborating with Mölnlycke, AstraZeneca and Devicia, we hosted an open webinar “Successfully navigating MDR transition” which aimed to inspire Sweden-based, small & medium sized companies (SMEs) how to navigate the transition towards alignment with the new EU Medical Device Regulation (MDR).

If you are a SME and would like to receive the presentation, contact [Amanda.Lantz@devicia.com](mailto:Amanda.Lantz@devicia.com)

### **Seven Q3 updates from BioVentureHub companies**

- [Amferia's](#) Anand Kumar Rajasekharan was recognized as “Årets Nybyggare 2020” in West Sweden.
- [Antaros Medical](#), in collaboration with Sanofi, presented data at EASD 2020 on the development of a Positron Emission Tomography (PET) ligand for the receptor of the incretin hormone Gastric Inhibitory Polypeptide (GIP).
- [Cereno Scientific](#) announced that the company will advance the development of drug candidate CS1 as an epigenetic modulator of rare diseases with orphan drug potential.
- [OnDosis](#) announced the signing of an extensive co-development agreement with Tiefenbacher Group to develop and commercialize innovative products within individualized treatments and digital health.
- [Promimic](#) shared study results showed that HAnano Surface modified implants outperformed machined and double acid etched implants in both normal and compromised bone.
- [Promimic](#) also announced the Innovasis, Inc. special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first spinal interbody devices modified with HAnano Surface. This was the first special 510(k) FDA approval of a device with HAnano Surface.
- [SDS Life Science](#) has a new name, a new look and a new CEO.

### **Looking ahead...**

Stay tuned for announcements relating to more exciting companies joining the BioVentureHub during Q4; exposing AstraZeneca to more science and technologies and adding to the 4D (drugs, devices, diagnostics, digital solutions) life science environment we are catalyzing.

We are also planning to launch a new version of the [BioVentureHub website](#) during Q4. This will give us more flexibility to highlight the support we provide to SMEs and to feature how we are contributing in areas such as sustainability, diversity and digital health.

**Before you go...**

Thank you so much for your continued support and encouragement. It is sincerely appreciated.

For more information about the BioVentureHub, please see:

- [BioVentureHub – One pager](#)
- [BioVentureHub – Infographic](#)
- [BioVentureHub – LinkedIn](#)
- [BioVentureHub – Website](#)
- [BioVentureHub – Twitter](#)
- [BioVentureHub – Project report](#)
- [BioVentureHub – Book \(in Swedish\)](#)
- [Workplace \(AstraZeneca employees only\)](#)

Take care and stay healthy!

*Magnus*

Magnus Björsne

CEO, AstraZeneca BioVentureHub